DBS in Treatment Resistant Major Depression
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01268137 |
Recruitment Status : Unknown
Verified December 2010 by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau.
Recruitment status was: Active, not recruiting
First Posted : December 29, 2010
Last Update Posted : December 29, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Resistant Major Depressive Disorder | Procedure: Deep Brain Stimulation | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 8 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | DEEP BRAIN STIMULATION IN TREATMENT RESISTANT MAJOR DEPRESSION. Controlled and Crossed Study on Efficacy and Safety. |
Study Start Date : | January 2008 |
Estimated Primary Completion Date : | June 2011 |
Estimated Study Completion Date : | June 2011 |

Arm | Intervention/treatment |
---|---|
Active Comparator: stimulation on
At first stage, electrodes will be implanted in all patients, who will be continuously stimulated for several months. After this stage, the random-crossed part of the study will start, and patients who responded to DBS will be randomly distributed in two groups: on stimulation or off stimulation group, for the next three months. Subsequently, patients will be allocated in the other group (on or off, crossed part) for three months
|
Procedure: Deep Brain Stimulation
Surgical electrode implantation in the white matter adjacent to the Cg25 region and implantation of the DBS pulse generating device |
Placebo Comparator: Stimulation off
At first stage, electrodes will be implanted in all patients, who will be continuously stimulated for several months. After this stage, the random-crossed part of the study will start, and patients who responded to DBS will be randomly distributed in two groups: on stimulation or off stimulation group, for the next three months. Subsequently, patients will be allocated in the other group (on or off, crossed part) for three months
|
Procedure: Deep Brain Stimulation
Surgical electrode implantation in the white matter adjacent to the Cg25 region and implantation of the DBS pulse generating device |
- Hamilton Rating Scale for Depression, 17-item version (HRSD-17) [ Time Frame: Psychiatric assessments will be performed every two weeks ]
- Montgomery-Asberg Depression Rating scale (MADRS) Clinical Global Impression (CGI) of Severity/Improvement Neuropsychological variables [ Time Frame: Psychiatric assessments will be performed every two weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients of both sexes aged between 18 and 70 years.
- Patients diagnosed as having an MDD episode according to DSM-IV-TR criteria, resistant to pharmacological treatment with a score of 4 in the Thase-Rush index, with ECT contraindicated or having failed to produce a maintained response.
- Patients with a HRSD-17 score of 18 or more.
- Patients with an intellectual capacity that facilitates adequate communication and who are willing to cooperate with all the examinations and protocols of the study.
- Patients who have not modified their antidepressant treatment in the month prior to the study.
- Women of childbearing age using medically approved contraceptive methods.
- Patients who have granted their informed consent in writing.
Exclusion Criteria:
- Female patients who are pregnant or breastfeeding.
- Patients with acute, serious or unstable illnesses.
- Patients experiencing delirium or hallucinations, congruent or otherwise with their mood.
- Patients with a history of substance abuse (other than tobacco or caffeine).
- Patients with concomitant psychiatric disorders from axes I or II of DSM IV-TR.
h)Patients with general contraindications for DBS (pacemaker users, etc).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01268137
Spain | |
Hospital Santa Creu i Sant Pau | |
Barcelona, Spain, 08025 |
Principal Investigator: | Perez Sola Víctor, MD | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | |
Principal Investigator: | Molet Joan, MD | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau |
Responsible Party: | Jordi Virgili, Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau |
ClinicalTrials.gov Identifier: | NCT01268137 |
Other Study ID Numbers: |
DEP-012004 |
First Posted: | December 29, 2010 Key Record Dates |
Last Update Posted: | December 29, 2010 |
Last Verified: | December 2010 |
MDD DBS |
Depressive Disorder Depressive Disorder, Major Mood Disorders Mental Disorders |